

Fig. 2

Days of Incubation	Relative Increase in Total pre-pro-B Cell Activity/Well
0	0
1	~1.2
2	~2.2
3	~3.2
6	~7.5

Days of Incubation

Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 9




Fig. 10




Fig. 11

Anti-PPBSF Co-F mAb
(clone A4)




Fig. 12

[illegible]

Fig. 13




Fig. 14




Fig. 15

1 2

2230 -

840 -



FIG. 16




FIG. 17

Fig. 18




Fig. 19




Fig. 20





Fig. 21



Days of rIL-7
Treatment

0

4

7

9

12

B220

A B220⁺

B B220⁺CD43⁺

C B220⁺CD43⁻




FIG. 22




FIG. 23




FIG. 24




FIG. 25A




FIG. 25B




FIG. 26

Treatment




FIG. 27


[illegible]

FIG. 28

Pretreatment




FIG. 29